

Morning Wrap

Today's Newsflow

Select headline to navigate to article

Ryanair Q1 results due on the 20th of July

Economic view Irish mortgage approvals hit a new high in May

Equity Research

26 Jun 2026

08:32

Upcoming Events

Company Events

Economic Events

Ireland

29-Jun	Retail Sales
01-Jul	ILO Unemployment Rate
03-Jul	GDP

United Kingdom

29-Jun	BoE Mortgage Approvals
	M4 Money Supply
30-Jun	GDP
	Exports
	Imports
01-Jul	S&P CIPS Manufacturing PMI
03-Jul	S&P CIPS Composite PMI
	S&P CIPS Services PMI

Goodbody Capital Markets

Equity Research +353 1 6419221

Equity Sales +353 1 6670222

Bloomberg DS GDS<GO>

Ryanair Q1 results due on the 20th of July

In advance of Q1 results on the 20th of July we update forecasts for FY27 and beyond. We believe close-in bookings have remained robust with the biggest change to forecasts being due to lower fuel. Jet fuel remains elevated versus the pre-war level but it is now lower than at any stage since the war in Iran began. As such the increase in Ryanair's fuel bill is now expected to be lower than before. However, this is something that will benefit the whole industry and we now expect yields in H2 and beyond to be somewhat lower than before. Putting it all together we expect Q1 net income of €595m and our new FY27 net income forecast is €1.99bn versus our previous forecast at €1.93bn.

Investors will be looking for an update on trends in Q2. At the FY26 results, travel demand for summer 2026 was described as robust although bookings were closer-in. Pricing had "eased somewhat" in recent weeks and at that stage Q2 pricing was trending broadly flat although the final outcome was dependent on close-in bookings. We are forecasting -0.5% yoy for Q2 fares. Elsewhere we will be looking for an update on the trajectory of unit costs after management commented that unit costs could increase by as much as mid-single digits although jet fuel is lower now. At this stage we don't expect anything new on the share buyback.

We value Ryanair using an EV/EBITDA methodology. After updating forecasts and leaving our valuation multiple unchanged our new PT is €31.00 and we remain on a BUY recommendation.

[Home...](#)

Recommendation: Buy
Closing Price:€27.40

Dudley Shanley
+353-1-641 9174
dudley.c.shanley@goodbody.ie

Economic view Irish mortgage approvals hit a new high in May

May was a notably strong month for mortgage approvals in Ireland, according to the latest BPGI data, with both volumes and values posting solid annual gains. Approval volumes rose by 13% yoy while values increased by 17% yoy, pointing to continued momentum in housing demand. Our own seasonal adjustment suggests that approvals for home purchase were particularly robust, with volumes rising by 9% to 4,139, a series high dating back to 2017. Within this, first-time buyers continue to dominate activity. The value of approvals to FTBs rose by 6% year-on-year over the latest three-month period, maintaining a pattern evident in recent years. This strength reflects a combination of underlying demand and the ongoing role of policy supports, notably Help-to-Buy and the First Home Scheme, which remain central to new-build activity. At the same time, mover activity has shown clear signs of improvement. In the three months to May, approval values for movers rose by 5% year-on-year, a marked turnaround from the slight contraction seen in the previous period.

Elsewhere, the remortgaging and top-up segment also recorded a significant pickup in activity. This category accounted for 21.4% of total approvals in May, with volumes rising by 29% and values by 40% compared to a year earlier. The three-month trend is similarly firm, with volumes up 12% and values increasing by 18% year-on-year. This acceleration appears to reflect, at least in part, a degree of front-loading ahead of the ECB's June rate increase, as borrowers moved to secure more favourable terms in advance of tighter monetary conditions.

In light of the recent geopolitical uncertainty and the fall in consumer confidence in Ireland, the mortgage market is showing itself to be robust. We expect this to result in a mortgage market of €15.6bn this year, representing growth of 6% and a new high in the post-GFC period.

[Home...](#)

Dermot O'Leary
+353-1-641 9167
dermot.c.oleary@goodbody.ie

Issuer & Analyst Disclosure

Analyst Certification

The named Research Analyst certifies that: (1) All of the views expressed in this research report accurately reflect my personal views about any and all of the subject securities and issuers. (2) No part of my remuneration was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this report.

Regulatory Information

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland and Goodbody Stockbrokers UC is authorised and regulated in the United Kingdom by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a wholly owned subsidiary of Allied Irish Banks, p.l.c. This publication has been approved by Goodbody. The information has been taken from sources we believe to be reliable, we do not guarantee their accuracy or completeness and any such information may be incomplete or condensed. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. The information, tools and material presented in this document are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

Conflicts of Interest

Goodbody has procedures and policies in place to identify and manage any potential conflicts of interest that arise in connection with its research business. Goodbody analysts and other staff who are involved in the preparation and dissemination of research operate and have a management reporting line that is independent to its business. Information barriers are in place between the Corporate Finance arm and the Research arm to ensure that any confidential and or price sensitive information is handled in an appropriate manner.

Our Investment Research Conflicts of Interest Policy is available at [Conflicts of Interest](#)

Investors should be aware, that, where appropriate, research may be disclosed to the issuer(s) in advance of publication, in order to correct factual inaccuracies only and not to materially amend the research in any way. Goodbody is satisfied that it has operational procedures in place, which ensure that such disclosures will not compromise the report's objectivity.

Goodbody Stockbrokers acts as corporate broker to Ryanair

Goodbody has provided investment banking services in the past 12 months to Ryanair

The list of companies for which Goodbody acts as market maker and on which it provides research, is available at [Regulatory Disclosures](#)

Other disclosures

We would like to inform you that Dudley Shanley holds shares in Ryanair

A description of this company is available at [Company Descriptions](#)

All prices used in this report are as at close of business of the previous working day unless otherwise indicated.

The time of publication of the report is Irish Standard Time (UTC +1), which accounts for transitions between IST and GMT (i.e. daylight saving time).

A summary of our standard valuation methods are available at [Valuation Methodologies](#)

A summary of share price recommendations and whether material investment banking services have been provided to these companies is available at [Regulatory Disclosures](#)

Other important disclosures are available at [Regulatory Disclosures](#)

Goodbody updates its recommendations on a regular basis. A breakdown of all recommendations provided by Goodbody is available at [Regulatory Disclosures](#) Where Goodbody has provided investment banking services to an issuer, details of the proportion of buys, holds and sells attributed to that issuer will also be included. This is updated on a quarterly basis.

Recommendation Definitions

Goodbody uses the terms "Buy", "Sell" and "Hold". The term "Buy" means that the analyst expects the security to appreciate in excess of 10% over a twelve month period. The term "Sell" means that the security is expected to decline in excess of 10% over the next twelve months. The term "Hold" means that the analyst expects the security to neither appreciate more than 10%, or depreciate more than 10% over the next twelve months.

On 26th November, 2012, the terms "Add" and "Reduce" were removed from the Recommendation Definitions and both were replaced with the "Hold" recommendation. Any Previous Recommendation that refers to either an "Add" means that the analyst expected the security to appreciate by up to 15% over a twelve month period. Any Previous Recommendation to "Reduce" means that the analyst expected the security to decline by up to 15% over the next twelve months.

In the event that a stock is delisted the firm will automatically cease coverage. If however the firm ceases to cover a stock for any other reason the firm will disclose this fact.

Distribution of Research to US Investors

Goodbody Stockbrokers UC acts as a market maker and distributes investment research to US major institutional investors and all transactions by US persons involving securities of companies discussed in reports distributed by Goodbody Stockbrokers UC are to be effected via Goodbody Securities, Inc. ("GSI"), a member firm of FINRA and SIPC. GSI is an affiliate of Goodbody Stockbrokers UC and does not act as a market-maker or maintain any positions in any security.

Neither GSI nor its affiliates hold a proprietary position and/or controls on a discretionary basis more than 0.5% of the total issued share capital of the issuer(s) covered by this report.

Details of all such positions that are the subject of the research are disclosed in the research reports and at www.goodbody.ie/legal-and-regulatory-disclosures/. This information was current as of the last business day of the month preceding the date of the report.

An affiliate of GSI may have acted, in the past 12 months, as lead manager/co-lead manager of a publicly disclosed offer of the securities in this company. Investors should be aware that an affiliate of GSI may have provided investment banking or non-investment-banking services to, and received compensation from this company in the past 12 months or may provide such services in the next three months. The term investment banking services includes acting as broker as well as the provision of corporate finance services, such as underwriting and managing or advising on a public offer.

Estimates/forecasts developed by Goodbody Research may not be met. Additional information is available, upon request to Goodbody Research, about the bases and assumptions behind the conclusions reached in Research reports.

Disclaimer

While all reasonable care has been taken in the production and dissemination of this report it is not to be relied upon in substitution for the exercise of independent judgement. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you.

Private customers having access, should not act upon it in anyway but should consult with their independent professional advisors. The price, value and income of certain investments may rise or may be subject to sudden and large falls in value. You may not recover the total amount originally invested. Past performance should not be taken as an indication or guarantee of future performance; neither should simulated performance. The value of securities may be subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities.

All material presented in this report, unless specifically indicated otherwise is copyright to Goodbody. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Goodbody.

Goodbody, 9-12 Dawson Street, Dublin 2, Ireland

T (+353 1) 6670400 **W** www.goodbody.ie **E** research@goodbody.ie